Prognostic relevance of urokinase plasminogen activator detection in micrometastatic cells in the bone marrow of patients with primary breast cancer
1997

Prognostic Relevance of Urokinase Plasminogen Activator in Breast Cancer

Sample size: 280 publication Evidence: high

Author Information

Author(s): E-F Solomayer, IJ Diel, D Wallwiener, S Bode, G Meyberg, M Sillem, Ch Gollan, MD Kramer, U Krainick, G Bastert

Primary Institution: University of Heidelberg

Hypothesis

The study aims to evaluate the prognostic relevance of urokinase plasminogen activator (uPA) detection in disseminated tumor cells in bone marrow of patients with primary breast cancer.

Conclusion

The presence of uPA-positive cells in bone marrow is associated with a significantly shorter metastasis-free interval and overall survival in breast cancer patients.

Supporting Evidence

  • 35% of patients with uPA-positive cells in bone marrow developed metastatic disease.
  • Patients with uPA-positive cells had a median metastasis-free interval of 36 months.
  • Patients with both uPA-positive and 2E11-positive cells had the worst prognosis.

Takeaway

This study found that if breast cancer cells in the bone marrow have a certain marker (uPA), it means the patient might have a worse outcome and may need more aggressive treatment.

Methodology

Bone marrow was sampled from patients and analyzed for the presence of uPA-positive tumor cells using immunocytological staining.

Limitations

The study may not account for all factors influencing metastasis and relies on specific markers that may not capture the full complexity of tumor behavior.

Participant Demographics

The study included 280 patients with primary breast cancer, with a mix of premenopausal and postmenopausal women.

Statistical Information

P-Value

p<0.001

Confidence Interval

95% CI 1.45-5.86 for metastasis-free survival

Statistical Significance

p<0.001

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication